|
Synonyms: glunozumab
Compound class:
Antibody
Comment: Glunomab is a mouse monoclonal antibody that is designed to block tissue-type plasminogen activator (tPA)-mediated potentiation of N-methyl-D-aspartate (NMDA) glutamate receptor function in neuroendothelial cells [2]. The antibody targets a regulatory site within the N-terminal domain of the human GluN1 (GRIN1) subunit of NMDA receptors, and prevents tPA binding. This mechanism is proposed to reduced tPA-mediated immune cell transmigration across the blood-brain barrier and is expected to counteract neuroinflammatory damage that is observed in neurological diseases such as multiple sclerosis, Parkinson's disease and stroke [1,3].
Lys Therapeutics' clinical lead LYS241 with this mechanism of action is a humanised and matured version of glunomab. |
